Akoya Biosciences (AKYA)
(Delayed Data from NSDQ)
$2.20 USD
+0.11 (5.26%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $2.21 +0.01 (0.45%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKYA 2.20 +0.11(5.26%)
Will AKYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKYA
Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
AKYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for AKYA
Hold Rating on Akoya Biosciences Amidst Solid Operations and Market Headwinds
Akoya Biosciences just downgraded at Morgan Stanley, here's why
Akoya Biosciences price target lowered by 50c at Craig-Hallum, here's why
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Alignment Healthcare (ALHC) and Akoya Biosciences (AKYA)
Akoya Biosciences (AKYA) was downgraded to a Hold Rating at BTIG